KEPHAS PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
KEPHAS PHARMA
Largest movements
- Cash +€13,118
up €13,118 (+62.3%), from €21,070 to €34,188
mainly Net result for the year (+€7,346) and Tax, wage and social debts (+€5,198)
- Deferred charges and accrued income -€2,795
down €2,795 (-52.4%), from €5,332 to €2,537
- Reserves +€7,346
up €7,346 (+31.7%), from €23,160 to €30,505
- Tax, wage and social debts +€5,198
up €5,198 (+34.7%), from €14,976 to €20,174
- Trade debts -€1,756
down €1,756 (-31.1%), from €5,654 to €3,898
- Gross operating margin -€16,801
down €16,801 (-54.7%), from €30,726 to €13,925
- Taxes -€3,705
down €3,705 (-62.1%), from €5,969 to €2,264
- Other operating charges +€2,719
up €2,719 (+197.8%), from €1,375 to €4,094
- Financial income +€457
up €457 (+228290.0%), from €0 to €457
- Financial charges +€455
up €455 (+204.0%), from €223 to €678
From the 2023 result to the 2024 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2023 and 2024 balance sheets and the 2024 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €46,790 | €57,577 | +€10,787 | +23.1% |
| Current assets | 29/58 | €46,790 | €57,577 | +€10,787 | +23.1% |
| Amounts receivable within one year | 40/41 | €20,388 | €20,852 | +€464 | +2.3% |
| Trade receivables | 40 | €15,977 | €10,863 | -€5,114 | -32.0% |
| Other amounts receivable | 41 | €4,411 | €9,988 | +€5,578 | +126.5% |
| Cash at bank and in hand | 54/58 | €21,070 | €34,188 | +€13,118 | +62.3% |
| Deferred charges and accrued income | 490/1 | €5,332 | €2,537 | -€2,795 | -52.4% |
| Total equity and liabilities | 10/49 | €46,790 | €57,577 | +€10,787 | +23.1% |
| Equity | 10/15 | €26,160 | €33,505 | +€7,346 | +28.1% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Reserves | 13 | €23,160 | €30,505 | +€7,346 | +31.7% |
| Distributable reserves | 133 | €23,160 | €30,505 | +€7,346 | +31.7% |
| Amounts payable | 17/49 | €20,630 | €24,071 | +€3,441 | +16.7% |
| Amounts payable within one year | 42/48 | €20,630 | €24,071 | +€3,441 | +16.7% |
| Trade debts | 44 | €5,654 | €3,898 | -€1,756 | -31.1% |
| Suppliers | 440/4 | €5,654 | €3,898 | -€1,756 | -31.1% |
| Taxes, remuneration and social security | 45 | €14,976 | €20,174 | +€5,198 | +34.7% |
| Taxes | 450/3 | €14,976 | €20,174 | +€5,198 | +34.7% |
| Other operating charges | 640/8 | €1,375 | €4,094 | +€2,719 | +197.8% |
| Gross operating margin | 9900 | €30,726 | €13,925 | -€16,801 | -54.7% |
| Operating profit (loss) | 9901 | €29,351 | €9,831 | -€19,520 | -66.5% |
| Financial income | 75/76B | €0 | €457 | +€457 | +228290.0% |
| Recurring financial income | 75 | €0 | €457 | +€457 | +228290.0% |
| Financial charges | 65/66B | €223 | €678 | +€455 | +204.0% |
| Recurring financial charges | 65 | €223 | €678 | +€455 | +204.0% |
| Profit (loss) for the period before taxes | 9903 | €29,129 | €9,610 | -€19,519 | -67.0% |
| Income taxes | 67/77 | €5,969 | €2,264 | -€3,705 | -62.1% |
| Profit (loss) for the period | 9904 | €23,160 | €7,346 | -€15,814 | -68.3% |
| Profit (loss) for the period to be appropriated | 9905 | €23,160 | €7,346 | -€15,814 | -68.3% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2023 and 31 December 2024. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.